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Summary Twenty-one patients with poor prognosis nonseminomatous germ cell tumours (six with extreme
burden disease at presentation in whom partial remission had been achieved with initial induction therapy, and
15 with recurrent disease after induction therapy) were treated with high-dose chemotherapy and autologous
bone marrow transplantation (BMT). The first six received etoposide 3.0 g m2, ifosfamide 6.0 gm-2 and
carboplatin 1.2 g m-2 (Regimen 1), and the subsequent 15 received etoposide 2.4 gm2 (continuous infusion),
cyclophosphamide 7.2 g m-2 and carboplatin 0.8 g m-2 (Regimen 2) followed by infusion of previously stored
autologous marrow.
Regimen 1 was associated with considerable renal toxicity and mucositis, whereas Regimen 2 was relatively
well tolerated. Two patients died as a consequence of the treatment: one of candidemia and one of interstitial
pulmonary fibrosis. Only one of 17 patients who were autografted in or approaching marker remission
subsequently developed disease progression (event-free survival 82%, 95% confidence interval [CI] 55% to
94%), whereas all four patients who had progressive disease at autografting subsequently developed further
disease progression and died. Fourteen patients remain well and free of disease 0.5 to 6.5 years (median 3.3)
post-BMT (event-free survival 67%, 95% CI 43% to 83%).
A strategy of prompt reinduction followed by high-dose chemotherapy and autologous BMT at thefirst sign
of failure of standard therapy may allow cure to be a realistic expectation.
The advent of platinum-based chemotherapy allowed the
expectation of cure for most patients with nonseminomatous
germ cell tumours (Einhorn, 1990; Feuer et al., 1991). How-
ever, for those with disease that either fails to remit or recurs
after such therapy the prognosis is poor (Loehrer Sr et al.,
1988; Harstrick et al., 1991). Approaches to treatment in this
latter group include use of noncrossresistant drugs as well as
augmentation of dose intensity (Coppin et al., 1992).
In an attempt to exploit the steep dose-response curve of
some drugs, autologous bone marrow transplantation (BMT)
has been used to permit the administration of cytotoxic
therapy in doses otherwise precluded by prolonged myelosup-
pression (Keating, 1992). When this strategy is applied to
patients with advanced refractory malignant disease (Cheson
et al., 1989), including germ cell tumours (Broun et al., 1992),
remissions are generally disappointingly brief. Nevertheless,
experience with Hodgkin's disease (Reece et al., 1991) sug-
gests that high-dose chemotherapy and autologous BMT
('autografting') might be more successful if employed earlier
for chemoresponsive disease.
Against this background, a study was commenced to
evaluate high-dose chemotherapy and autologous BMT in
the treatment of patients with nonseminomatous germ cell
tumours in whom cure with conventional therapy was con-
sidered unlikely.
Methods
Strategy
The overall strategy developed in Vancouver for the manage-
ment ofpatients with poor prognosis nonseminomatous germ
cell tumours, based on a high-intensity cisplatin-etoposide
(HIPE) program (Murray et al., 1987), has been described
elsewhere (Coppin et al., 1992). In brief, HIPE (cisplatin
80 mg m-2 plus vincristine 0.6 mg m-2 on day 1 and
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etoposide 100 mg m-2 on days 1 and 2) is given weekly
(provided the neutrophil count > 0.5 x 109 L-') to patients
with high burden disease (Birch et al., 1986) at presentation
and those with recurrent disease after other cisplatin-based
chemotherapy protocols. Early in the series, patients received
5 to 11 cycles of HIPE until they were in or approaching
marker remission before consideration of consolidation with
high-dose chemotherapy Regimen 1 (see below). With the
introduction of Regimen 2, the trend has been to give five
cycles over weeks 0 to 5 and then consolidate with one or
two cycles of VIP (Loehrer Sr et al., 1986).
Eligibilityfor autografting
Two groups of patients were eligible for high-dose
chemotherapy and autologous BMT: (1) patients with ex-
treme burden disease (extrapulmonary visceral metastases or
HCG> 105 or AFP> 104) at presentation, in whom only
partial remission was achieved with induction therapy (high
risk group); (2) patients with unequivocal disease progression
during or after cisplatin-based chemotherapy (salvage
group).
Patients
Between March 1986 and April 1992, 21 male patients aged
16 to 38 years (median 28) underwent high-dose
chemotherapy and autologous BMT. Six patients with ex-
treme burden disease at presentation had achieved partial
remission with initial induction therapy (Table I). Fifteen
patients had developed recurrent disease during or after
induction therapy (Table II)
All patients except one had disease of nonseminomatous
primary histology, with or without seminoma. In the one
who did not (UPN 498), the histology was pure seminoma,
but the AFP was elevated at recurrence.
The treatment protocol was approved by the local review
boards and patients gave informed consent prior to entry
into the study.
High-dose chemotherapy regimens
Two high-dose chemotherapy regimens were employed
(Figure 1). The first six patients received Regimen 1, in which
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Table I Details of patients autografted as consolidation of first partial remission
Adverse risk factors Induction Dominant marker
UPN at presentation chemotherapy Pre-induction Pre-BMT
192 Mediastinal primary; HIPE AFP: 12,000 <3
CEA
305 Advanced lung HIPE, VIP-B HCG:390,000 20
327 Advanced lung HIPE HCG:370,000 60
406 Lung, liver, bulky nodes; HIPE, VIP HCG:228,000 20
Choriocarcinoma
503 Advanced lung, stomach, skin; HIPE, VIP HCG:430,000 7
Choriocarcinoma
507 Lung, liver; BEP, VIP HCG:855,000 20
Choriocarcinoma
Abbreviations: UPN, unique patient number; CEA, carcinoembryonic antigen; AFP,
alphafetoprotein (normal <20 ng mL-'); HCG, human chorionic gonadotropin (normal
< 5 mU mL-'); HIPE, high-intensity cisplatin-etoposide; VIP, VP-16 (etoposide),
ifosfamide and cisplatin; B, bleomycin; BEP, bleomycin, etoposide and cisplatin.
Note. All patients had residual masses pre-BMT and one (UPN 192) underwent
resection which showed viable residual carcinoma. Two patients had evidence of
progressive disease, UPN 305 on chest radiograph pre-BMT and UPN 503 on HCG level
between HIPE and VIP.
Table II Details of patients autografted for recurrent disease
At recurrence
Months off Reinduction
UPN Previous therapy chemotherapy Active sites chemotherapy
104 HIPE-B, XRT 6 AFPt225 None
107 PVB 6 Liver, RN, AFP, HCG, LDH HIPE
119 PEVB 4 HCGt80 HIPE
147 PVB 9 RNt(6 cm) HIPE
158 PV a Lungt, AFP, HCG, LDH HIPE
242 PEVB 4 Lungt, RN+, AFPt HIPE
253 PV I Liver (bx) HIPE
309 PV a AFPt1650 HIPEb, VIPb
336 PV 7 AFPt95 HIPE, VIP
404 PV a Lung, AFPt49 HIPEb, VIPb, MMCb
436 PV a HCGt75 HIPE, VIP
498 PEB, XRT 9 Mediastinum, lung, AFP, HCG, LDH HIP(E), (V)IP
559 PVB a Mediastinum (bx), lungt, AFPt128 VIPb
700 EP, HIPE, XRT 5 Liver, RNt(7cm), HCGt490, LDH VIP
712 PV, HIPE, VIP 4 AFP+65 VIP
Abbreviations: UPN, unique patient number; AFP, alphafetoprotein (normal,<20ngmL-'); HCG, human
chorionic gonadotropin (normal <5 mU mL- ); LDH, lactate dehydrogenase; RN, retroperitoneal nodes; HIPE,
high-intensity cisplatin-etoposide; VIP, VP-16 (etoposide), ifosfamide and cisplatin; P, cisplatin; V, vinblastine; B,
bleomycin; E, etoposide; MMC, mitomycin; XRT, radiotherapy; bx, (proven by) biopsy.
Note. All patients had progressive disease during or after cisplatin-based chemotherapy. aIndicates the disease
progressed during or within 1 month of the previous therapy. bIndicates no response to or progression after
re-induction therapy. Patients UPN 700 and UPN 712 were treated after second and third recurrence, respectively,
having declined autografting earlier.
REGIMEN 1
Total Day
Agent dose -6 -5 -4 -3 -2 -1 0
Etoposide 3.0 g m-2 ./1 /1 ./0 B
Carboplatin 1.2g m-2 * M
Ifosfamide 6.0g m-2 T
REGIMEN 2
Total Day
Agent dose -6 -5 -4 -3 -2 -1 0
Etoposide
Carboplatin
Cyclophosphamide
2.4 gm-2
0.8 gm-2
7.2 gm-2
0 0 0
0 0 0 0
Figure 1 High-dose chemotherapy regimens.
B
M
T596 M.J. BARNETT et al.
etoposide 0.5 g m-2 was given as a 2 h IV infusion x 6 doses;
carboplatin 1.2 g m2 as a 3 h IV infusion x 1 dose; ifos-
famide 6.0 g m-2 as a 72 h IV continuous infusion; and
MESNA was used for uroepithelial protection. The subse-
quent 15 patients received Regimen 2, in which etoposide
2.4 gm-2 was given as a 34h IV continuous infusion; car-
boplatin 0.25 g m-2 as a 1 h IV infusion x 2 doses and
0.3 g m-2 as a 1 h IV infusion x 1 dose; cyclophosphamide
1.8 g m-2 as a 2 h IV infusion x 4 doses; and vigorous hydra-
tion was used for uroepithelial protection.
Autologous marrow transplantation
Marrow was aspirated, cryopreserved and infused according
to standard techniques (Herzig, 1981). The infusion of mar-
row (on day 0) was no earlier than 72 h after the last dose of
carboplatin and 48 h after the last dose ofcyclophosphamide.
The median (range) number of nucleated cells infused was 2.9
(1.0 to 5.2) x 108 kg-' of patient body weight.
Supportive care
Patients were managed in rooms equipped with high-
efficiency particulate air filtration and given antibiotics,
amphotericin, irradiated blood products and intravenous nut-
rition as indicated. Those seropositive for herpes simplex
virus received prophylactic acyclovir and those seronegative
for cytomegalovirus (CMV) received CMV-negative blood
products.
Regimen-related toxicity
Regimen-related toxicity was graded according to the criteria
proposed by the Seattle group (Bearman et al., 1988). In
brief, grades I and II were not life-threatening, the former
resolving spontaneously and the latter requiring intervention;
grade III was life-threatening but reversible, and grade IV
was fatal.
Statistical methods
Events (therapy-related death and disease progression) were
measured from the day of BMT and event-free survival plots
were developed according to the method of Kaplan and
Meier (Kaplan & Meier, 1958). Patients were censored on the
day of last follow-up. Results were analysed on November 9
1992.
Results
Haematological toxicity
Pancytopenia was universal. All patients, except one who
died on day 8 of Candida albicans septicemia (UPN 192),
made full haematological recoveries. The median day (range)
post-BMT to reach >0.5 x 109 L-l neutrophils and
>20 x 109L` platelets was 15(7 to 25) and 20(11 to 52),
respectively.
Nonhaematological toxicity
Grade II-IV nonhaematological toxicities related to the two
high-dose chemotherapy regimens are shown in Table III.
Table III Nonhaematological toxicity of high-dose chemotherapy
regimens
Regimen I (n = 6) Regimen 2 (n = 15)
Grade Grade
II III IV II III IV
Mucosal 5 - 9
Renal 2 2a _ b
Hepatic 1 - 4
Cardiac 1 3
Pulmonary - - - c
Gastrointestinal - - I
Urinary - - I
CNS - - -
aBoth required dialysis; one died of candidemia. bRequired
dialysis. cDied of interstitial pulmonary fibrosis.
The renal toxicity and mucositis encountered with Regimen 1
prompted the development of Regimen 2 in 1988. One
patient (UPN 305) died on day 33 of interstitial pulmonary
fibrosis.
Peripheral neuropathy and hearing loss post-BMT were
troublesome in some patients. In all except one (who con-
tinues to need a hearing aid), both problems resolved func-
tionally, although one patient required a prolonged period of
rehabilitation for a severe motor neuropathy.
Outcome
The outcome post-BMT according to disease status at study
entry and at autografting is shown in Table IV. Both patients
who died of therapy-related causes (UPN 192 and 305) had
no evidence of viable malignant disease at post-mortem
examination. Only one of 17 patients who underwent auto-
grafting in or approaching marker remission (UPN 507)
subsequently developed disease progression (event-free sur-
vival in this group was 82%, 95% confidence interval [CI]
55% to 94%). In contrast, all four patients who had progres-
sive disease at the time of autografting (UPN 104, 309, 404
and 559) developed further disease progression soon
thereafter and died.
The event-free survival plot is shown in Figure 2. One
patient (UPN 242) had a mass excised from the suprac-
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Figure 2 Event-free survival of all patients ( , n = 21), those
autografted for responding disease (- , n = 17) and those
autografted for progressing disease (..... n = 4).
Table IV Outcome according to disease status at study entry and at
autografting
Therapy-related Disease Event-free
Disease status n death progression survival
At study entry
First partial remission 6 2 1 3
Recurrence 15 0 4 11
At autografting
Responding 17 2 1 14
Progressing 4 0 4 0
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lavicular fossa 3 months post-BMT, the histology of which
was mature teratoma. Another (UPN 327) underwent
orchidectomy for an enlarging mass in the testicle 37 months
post-BMT, the histology of which was also mature teratoma.
These two patients and 12 others remain event-free 0.5 to 6.5
years (median 3.3) post-BMT (event-free survival 67%, 95%
CI 43% to 83%) and all enjoy robust health. All of these
patients are in marker remission and ten have normal
radiological examinations. Two patients (UPN 327 and 406)
had small static abnormalities on chest radiograph 43 months
and 33 months post-BMT, respectively; one (UPN 253) had a
small static abnormality on liver ultrasound 50 months post-
BMT; and one (UPN 700) had a shrinking inguinal mass on
computerised tomography scan 5 months post-BMT.
Discussion
High-dose chemotherapy and autologous BMT was incor-
porated into an overall strategy for the management of
patients with poor prognosis nonseminomatous germ cell
tumours (Coppin et al., 1992). The basic tenet of the study
was that patients with extreme burden disease at presentation
in whom partial remission had been achieved and those with
recurrent disease had a sufficiently poor prognosis to justify
the anticipated toxicities of autografting.
Two of the 21 patients died as a consequence of the
treatment. One of these deaths was due to interstitial pul-
monary fibrosis which was, in retrospect, developing prior to
the high-dose chemotherapy and probably related to
bleomycin given in conjunction with VIP. This death not-
withstanding, the therapy-related mortality of 10%, although
unfortunate, is acceptable under the circumstances.
The early course in the six patients who received Regimen 1
was characteristically eventful, with nephrotoxicity and
mucositis being common. Two of these patients required
dialysis, one of whom died of candidemia. The etiology of
the nephrotoxicity was likely multifactorial, but, as suggested
by others (Broun et al., 1991a), ifosfamide was probably
contributory. Accordingly, Regimen 2 was developed with
the substitution of cyclophosphamide (Buckner et al., 1974)
for ifosfamide as well as reduction in dose of carboplatin. In
addition, etoposide was given at a lower total dose and as a
continous infusion in an attempt to reduce mucositis (Phillips
et al., 1991). These revisions were probably beneficial, as
Regimen 2 was associated with less nephrotoxicity. More-
over, ifosfamide, which can undergo only modest dose
escalation (Elias et al., 1990), may be better employed earlier
for remission induction. Having established that the toxicity
of Regimen 2 is usually moderate, a judicious increase in the
carboplatin dose may be possible, perhaps according to pre-
treatment glomerular filtration rate (Calvert et al., 1989) as
excretion is mainly renal (Harland et al., 1984).
Chronic toxicity was limited to peripheral neuropathy and
hearing loss. These problems were exacerbations of toxicities
established pre-autografting and presumably caused by cis-
platin. For the most part, they eventually resolved sufficiently
so as not to be associated with significant morbidity.
Seventeen patients were in or approaching marker remis-
sion at the time of autografting. In this group there were two
therapy-related deaths (neither patient having evidence of
disease at post-mortem examination) but only one patient
subsequently developed progressive disease. Thus 82%
remain event-free, which is a most gratifying result. The
relative contribution of the components of the strategy, i.e.,
induction ofremission with HIPE and VIP and consolidation
with high-dose chemotherapy and autologous BMT, is not
possible to determine. Nevertheless, for these patients the
overall strategy is quite clearly an effective one. In contrast,
all four patients with progressive disease at the time of
autografting developed further disease progression soon
thereafter and such patients are unlikely to benefit from the
approach. It seems reasonable to suggest that the event-free
survival of 67% for the whole group is a better result than
might have been achieved with standard salvage
chemotherapy (Loehrer Sr et al., 1988; Harstrick et al.,
1991).
A number of studies utilising autologous BMT in the
treatment of germ cell tumours have been reported (Blijham
et al., 1981; Mulder et al., 1988; Nichols et al., 1989; Broun
et al., 1991a; Broun et al., 1991b; Droz et al., 1991; Siegert et
al., 1991; Motzer et al., 1992; Nichols et al., 1992; Rosti et
al., 1992). These may be summarised as follows: (1) The
majority of patients had far advanced disease and had
received considerable prior therapy. (2) High-dose
chemotherapy regimens were comprised of various combina-
tions of carboplatin, etoposide, cyclophosphamide and ifos-
famide. (3) Durable remissions were achieved in 10% to
25% of patients. (4) Patients with disease responsive to con-
ventional therapy at relapse were more likely to achieve
durable remission than those with refractory disease (Droz et
al., 1991; Rosti et al., 1992).
The improved results of this study may have a number of
explanations. First, most patients had disease which was still
responsive to a platinum-based regimen at induction and
reinduction. Second, bleomycin has been deleted from
routine use in Vancouver protocols since 1986 (Levi et al.,
1986) and it might be argued that weak induction therapy
(i.e., PV) made salvage easier. Third, three of the 14 event-
free survivors were treated as consolidation of first partial
remission. Until such time as prognostic factors can be relied
upon to predict failure of induction therapy, autografting in
first remission may be considered a somewhat contentious
issue.
It is concluded that the most useful role ofautografting for
nonseminomatous germ cell tumours is in the consolidation
of second remission. A strategy of prompt reinduction fol-
lowed by high-dose chemotherapy and autologous BMT at
thefirst sign of failure of standard therapy may allow cure to
be a realistic expectation.
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